BPC-157 postpartum recovery claims: what the evidence says

What did @doraefit actually say?

She spent four months self-managing what she calls "Ratatouille" — a TikTok code word for tirzepatide — without clinical supervision, adjusting her own doses, splitting injections, and tracking side effects on camera. Her headline claims: appetite suppression hit within 24 hours, sugar cravings vanished, she gained muscle, and her previously irregular periods became "spot on" regular for the first time since puberty. She also walked through a textbook case of what happens when you self-titrate aggressively: she upped her dose too early, spent a week in GI misery, tried split-dosing without understanding the pharmacokinetics, and crashed again. Credit where it's due — she was transparent about her mistakes rather than pretending everything went smoothly.

Does the science back this up?

The core pharmacology checks out, mostly. Tirzepatide is a dual GIP/GLP-1 receptor agonist. The rapid appetite suppression she described is consistent with the drug's mechanism. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed significant reductions in caloric intake and food preoccupation within the first weeks of treatment. GLP-1 receptor agonists are well-documented for reducing "food noise," which is the term researchers and patients use for intrusive thoughts about eating. Her GI side effects, nausea and diarrhea, are the most commonly reported adverse events in that same trial, affecting a significant portion of participants. The period regulation claim is the outlier. There is emerging but thin evidence that GLP-1 receptor agonists may improve menstrual regularity in women with PCOS or insulin resistance through weight loss and metabolic changes (Jensterle et al., 2019, Journal of Clinical Endocrinology and Metabolism), but the data is not robust enough to make a clean causal claim, especially without knowing her underlying diagnosis.

What did they get wrong (or right)?

She got the dose-escalation warning right, even if she learned it the hard way. Jumping doses before tolerating the current one is exactly what clinical guidelines caution against, and her week of "super nauseous and very bad bathroom 24-7" is a predictable consequence, not bad luck. Where she goes sideways is the split-dosing logic. She reasoned that splitting her weekly dose would keep drug levels steady throughout the week. That is not how tirzepatide works. It has a half-life of approximately five days, meaning plasma levels are already relatively stable week-to-week on a consistent regimen. Splitting the dose doesn't smooth out peaks; it just delivers half the dose twice and introduces new GI insult each time. Her instinct was wrong, and the outcome confirmed it. The period claim deserves skepticism. She says "I'm not 100% certain" herself, which is fair, but attributing menstrual regulation to tirzepatide specifically, rather than to postpartum hormonal normalization or weight changes, is a leap the evidence does not fully support yet.

What should you actually know?

A few things this video glosses over matter a lot. First, tirzepatide is not approved for muscle gain. It is approved for weight management and type 2 diabetes. Using it postpartum, without a supervising clinician adjusting doses, is real risk. The self-titration she describes, going up, crashing, splitting, crashing again, is exactly the scenario that clinical protocols exist to prevent. Second, "Ratatouille" as a code word exists because creators know these videos sit in a regulatory gray zone. That framing does not change what the drug is or what the risks are. Third, her disclaimer that this is "for research purposes only" does not actually limit the influence a 52,000-view video has on viewers who may be newly postpartum, undiagnosed, or without access to proper medical oversight. If you are considering a GLP-1 or GIP/GLP-1 agonist, the conversation starts with a licensed clinician who knows your full history, not a TikTok comment section.